Ron Bentsur

Mr. Ron Bentsur

Chairman of the Board

Mr. Ron Bentsur joined as AIT’s Chairman in August 2015.

Mr. Bentsur served as Chief Executive Officer of Keryx Biopharmaceuticals, Inc. and as a member of its board of directors from 2009 to April 2015. Mr. Bentsur’s tenure as CEO of Keryx Biopharmaceuticals culminated in the September 2014 FDA approval of AuryxiaTM (ferric citrate) and its December 2014 U.S. launch. Prior to joining Keryx Biopharmaceuticals, Inc. Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals, Ltd. from 2006 to 2009. From 2000 to 2006, Mr. Bentsur worked for Keryx Biopharmaceuticals, where he also served as Vice President Finance and Chief Financial Officer from 2003 until 2006. From 1998 to 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology and biotechnology private placement and advisory transactions. From 1994 to 1998, Mr. Bentsur was a New York City-based investment banker, primarily at ING Barings Furman Selz.

Mr. Bentsur holds a B.A. in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an M.B.A., magna cum laude, from New York University’s Stern Graduate School of Business.

Yossi Av-Gay

Prof. Yossef Av-Gay

Co-Founder and Chief Scientific Officer

Professor Yossef Av-Gay co-founded and became a director of AIT in 2011. He became chief scientific officer in 2012 and was appointed AIT’s chairman from 2014 to 2015.

He is engaged in translational research of bacterial pathogens aimed at antimicrobial drug development. Since 1997, Prof. Av-Gay has been on the Faculty of Medicine Division of Infectious Diseases at the University of British Columbia, where he teaches microbiology.

He consults to several pharmaceutical and biotechnology companies and is a member of the scientific review panels of the Canadian Institute of Health Research (since 2010), the French Agence Nationale de la Rechereche (since 2008), Innovative Medicine Innovations, the U.S. National Institutes of Health (since 2010), the European Commission FP6, FP7 (since 2002), and Horizon 2020 (since 2014).

Prof. Av-Gay holds a Ph.D. in molecular microbiology, an M.Sc. in microbiology, and a B.Sc., in biology, all from Tel Aviv University.

Amir Avniel

Mr. Amir Avniel

Co-Founder, Chief Executive Officer and Director

Mr. Amir Avniel co-founded AIT in 2011 and became a director at that time.

Mr. Avniel has over 12 years of management experience in product development and product marketing, leading large teams from diverse backgrounds and industries to operational excellence. Mr. Avniel served as an executive on the Monsanto Israel business team and prior its purchase by Monsanto, Mr. Amir served as the President and Chief Executive Officer of Rosetta Green Ltd.
Mr. Avniel served as president and Chief Executive Officer of Rosetta Genomics (Nasdaq: ROSG). Under Amir’s leadership Rosetta Genomics went public in a NASDAQ IPO


Mr. David Grossman


David Grossman has served as a member of our board of directors since February 2016. Mr. Grossman serves as one of our directors and serves on our audit committee, compensation committee and balance sheet committee. He has served as an independent director and member of the compensation committee at Amnis Therapeutics Ltd. (TASE: AMNS) (formerly ITGI Medical Ltd.) since January 2015. He has also served as an external director and member of the audit and compensation committee at Cellect Biomed Ltd. (TASE: CLBD). Mr. Grossman served as chairman of the board of directors at Algomizer Ltd. (TASE: ALMO) from May 2014 to January 2016. Mr. Grossman served as Chief Executive Officer at XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL), from February 2009 until February 2014 and also member of the board from February 2009 to November 2013. He served as a Vice President of Eurocom Investments LP, a private equity fund, from March 2006 to January 2009. Also from March 2006 to January 2009, Mr. Grossman served as Vice President of Sahar Investments Ltd, (TASE: SAIN, today Enlight Energy: ENLT) which focused on investments in the Life Sciences arena. From July 2003 to March 2006, Mr. Grossman was a Senior Analyst at Israel Health Care Ventures (IHCV), an Israeli healthcare venture capital fund. From November 2012 until September 2013, Mr. Grossman served as a director in Proteologics Ltd. (TASE: PRTL). Also from July 2012 until November 2013, Mr. Grossman served as a director in InterCure Ltd. (TASE: INCR). Since August 2011 until August 2014, Mr. Grossman served as an external director and member of the audit committee of Rosetta Green Ltd. (TASE: RSTG). From January 2009 to April 2011, Mr. Grossman was a director and member of the audit committee of Bio Light Israeli Life Science Investments Ltd. (TASE: BOLT), and from May 2007 to July 2008 was a Director and member of the audit committee of Gilat Satcom Ltd. (AIM: GLT).

Mr. Grossman received a BA business administration with a focus on information technology, from the Interdisciplinary Center Herzliya.

Ari Raved

Mr. Ari Raved


Since 2004, Mr. Ari Raved has served as senior VP of IDB Development Corp. Ltd., a subsidiary of IDB Holding Corp. Ltd. Mr. Raved is also a director of Property and Building Corporation, Gav-Yam Bayside Land Corporation, and Modiin Energy LP. He is chairman of Bartan Holdings and Investments Ltd. In the past, Mr. Raved held management positions at Bank Leumi and was a director at a number of companies.

Mr. Raved holds an M.A. in labor studies from Tel Aviv University.

Jerome B Zeldis

Dr. Jerome B. Zeldis


Jerome B. Zeldis, M.D., Ph.D., joined our board in September 2015. Dr. Zeldis is the CEO of Celgene Global Health and the CMO of Celgene Corporation, and he previously served as Celgene’s Senior Vice President of Clinical Research and Medical Affairs. Since June 2011, he has served on the board of directors of Soligenix, Inc., and on the board of directors of Alliqua, Inc. and Bionor Pharma ASA since May 2012. In addition, Dr. Zeldis has previously served as Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at the University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received an A.B. and M.S. from Brown University and an M.Phil., M.D. and Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry) from Yale University.

Steve Lisi

Mr. Steve Lisi


For the past twenty years, Mr. Steve Lisi has played an instrumental role in analysis and investment in both private and public companies ranging from $2M to $250B market cap. For the first 18 years of his career he held variety of executive investment positions at Mehta & Isaly (now split into Orbimed and Mehta Partners), SAC Capital, Millennium Partners, and most recently as a managing partner at Deerfield Management, one of the leading healthcare investment firms on Wall Street. Following Deerfield he was responsible for restructuring Flamel Technologies, where he transformed the company from a $100M enterprise value to $1B in three years. His major finance related accomplishments included a $121M equity financing, sale of a contract manufacturing facility, reducing overhead by 50%, and the establishment of a presence in Ireland to allow for future tax optimization. His investment and executive management experience covers both pharmaceuticals and medical devices. He is the Co-Founder and Chairman of the Board of Mico Innovations, a next generation novel bare metal stent company and a board member of Trio Health, a leading edge healthcare IT company.

Mr. Lisi holds a Master in International Business from Pepperdine University.